Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 79

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Gaucher's disease type III

Not recruiting

Study on the Effectiveness and Safety of Venglustat for Adults and Children with Gaucher Disease Type 3

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adrenoleukodystrophy+1

Not recruiting

Study on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pramipexole Dihydrochloride Monohydrate
  • Sponsor:Amsterdam UMC Stichting

Post breast therapy pain syndrome+1

Not recruiting

Study Comparing Serratus Plane Block, Capsaicin, and Botulinum Toxin Type A for Chronic Pain in Post-Mastectomy Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Centre Oscar Lambret

Medulloblastoma

Not recruiting

Study on the Safety and Effectiveness of Methotrexate and Drug Combination for Children and Young Adults with High-Risk Metastatic Medulloblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Azienda Ospedaliera Universitaria Meyer IRCCS

Generalised tonic-clonic seizure+1

Not recruiting

Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prax-628
  • Sponsor:Praxis Precision Medicines Inc.

Insomnia

Not recruiting

Study on the Effect of Cannabidiol (CBD) on Sleep Quality in Multiple Sclerosis Patients with Insomnia

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Wageningen Research Stichting

Multiple sclerosis

Not recruiting

Study on the Effects of Cladribine on Brain Cells in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Cladribine
  • Sponsor:Varsinais-Suomen hyvinvointialue

Parkinson's disease

Not recruiting

Study on How Exenatide Affects Early Parkinson's Disease Progression in Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Exenatide
  • Sponsor:Region Stockholm – SLSO

Narcolepsy

Not recruiting

Study on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.

Dementia Alzheimer's type

Not recruiting

Study of Remternetug for Patients with Early Alzheimer's Disease at Risk for Cognitive and Functional Decline

Investigational
Countries:SpainSpain
  • Participants:65+ years
  • Substances:LY3372993
  • Sponsor:Eli Lilly & Co.

Glioma

Not recruiting

Study on the Safety and Effectiveness of Sirolimus for Treating High-Grade Glioma in Children

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of TolDec and Immunotherapy for Patients with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.